Literature DB >> 17048214

Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis.

Nancy Xu1, James F Glockner, Sandro Rossetti, Dusica Babovich-Vuksanovic, Peter C Harris, Vicente E Torres.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a common, inherited disorder characterized by the progressive enlargement of fluid-filled cysts in the kidneys and liver. Since the cystic fibrosis transmembrane conductance regulator (CFTR) Cl--channel may mediate the secretion of Cl--and fluid into the cysts, it is conceivable that coexisting cystic fibrosis (CF) in patients with ADPKD could attenuate their development. We previously reported that two patients with ADPKD coexisting with cystic fibrosis (CF) had a milder cystic phenotype than that of kindred without CFTR mutations. A subsequent report failed to confirm this protective effect. We now have identified another family with coexisting type 1 ADPKD and CF. The kidney volumes and the number and size of renal and hepatic cysts were markedly less in a member of this family with ADPKD (PKD1 mutation C508R) and CF (homozygous DeltaF508 mutation) than in her sister with ADPKD alone at comparable ages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048214

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  20 in total

Review 1.  Polycystic liver diseases: congenital disorders of cholangiocyte signaling.

Authors:  Mario Strazzabosco; Stefan Somlo
Journal:  Gastroenterology       Date:  2011-04-22       Impact factor: 22.682

2.  Acute renal failure in people with cystic fibrosis.

Authors:  Kevin W Southern
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

Review 3.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

4.  Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model.

Authors:  Lukmanee Tradtrantip; N D Sonawane; Wan Namkung; A S Verkman
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

Review 5.  Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Authors:  Wouter N Leonhard; Hester Happe; Dorien J M Peters
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

Review 6.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 7.  Determinants of renal disease variability in ADPKD.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

8.  Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.

Authors:  Baoxue Yang; Nitin D Sonawane; Dan Zhao; Stefan Somlo; A S Verkman
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

Review 9.  New treatments for autosomal dominant polycystic kidney disease.

Authors:  Ming-Yang Chang; Albert C M Ong
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 10.  CFTR inhibitors.

Authors:  Alan S Verkman; David Synder; Lukmanee Tradtrantip; Jay R Thiagarajah; Marc O Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.